

SGD Pharma introduces Clareo, its new premium range of molded glass vials in Type II, for injectable solutions.

Clareo

Clareo vials from SGD Pharma offer a combination of homogeneous wall thickness and superior cosmetic quality, which for molded glass Type II is unique in the market. The new range offers technical characteristics similar to the vials in the existing range and can replace them without any regulatory change. Once again, SGD Pharma demonstrates with Clareo its expertise in the control of manufacturing process of molded glass.

The mission of SGD Pharma, one of the world's leading manufacturers of glass containers for primary pharmaceutical packaging, is to improve and protect patients' health by supplying high quality, reliable and innovative glass primary packaging to customers in the pharmaceutical industry. Our commitment is to continuously innovate and to reinforce patient safety by improving the physical, chemical and cosmetic properties of our different types of glass.

Improved mechanical resistance, significant reduction in the breakage rate and improved inspectability



Clareo vials, for injectable solutions.

The mechanical resistance to shock of the Clareo vials has been considerably improved by obtaining a more homogeneous distribution of the glass (+15pts compared to the standard process). This increased regularity allows a significant reduction of the breakage rate (up to 10x lower).

Clareo vials have more flat and uniform bottoms, which ease the thermal transfer during freeze-drying processes.

Clareo vials also offer a superior cosmetic quality, leading to an improved inspectability before and after filling. Pharmaceutical and biotechnology companies benefit from this advantage, allowing a reduction of their Total Cost of Ownership (TCO), mostly for high value-added products.

Furthermore, customers looking for a more economical alternative to converting Type I glass can find a more affordable solution in Clareo. SGD Pharma can share a list of molecules, for which compatibility with glass Type II has been approved by the authorities.

SGD Pharma is currently the only manufacturer able to supply vials for injectable solutions in molded glass Type II, offering the combined benefits of transparency and strength.

Clareo is available in capacities of 20, 50 and 100ml in Type II and further developments are in progress. Clareo can also be available, on request, in Type III.



Relations presse / Press Release

Marie Respingue – Mepax – m.respingue@mepax.com - 06.65.59.84.20

Marketing & Communication SGD Pharma

Jean-Pascal Marquié – jean-pascal.marquie@sgdgroup.com